Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026 cover art

Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026

Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026

Listen for free

View show details

Summary

 🎙️ Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive- Part 2 Guests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026 We’re back with Part 2 of our atopic dermatitis double-header with Dr. Marissa Joseph and Dr. Fiona Lovegrove from AAD 2026 in Denver—and this time, we’re getting into the data that always enters the chat when JAK inhibitors in Atopic Dermatitis are mentioned: long-term safety. Our expert faculty unpack fresh 6-year safety data on upadacitinib in moderate-to-severe atopic dermatitis—looking beyond efficacy and into the real-world clinical questions dermatologists face every day: 🧩 Who is the right patient?⚖️ How do we balance real world risk vs benefit?👵 Does anything change when a patient is over 65? Or is it about how risk is really framed?💉 Where does zoster vaccination fit into the treatment conversation? 📊 And how do we contextualize MACE, VTE, malignancy, infections, and herpes zoster without turning nuance into noise? Because let’s be honest: when it comes to JAK inhibitors, the safety conversation doesn’t just knock politely—it pulls up a chair. 🪑 This episode dives into how long-term data can help clinicians move beyond blanket “yes/no” thinking and toward more individualized decision-making: age, comorbidity stacking, dose, baseline risk, quality of life, disease severity, and patient preference all matter. The big takeaway? Decisions in the gray zone—and that’s exactly where expert interpretation matters most. 🎯 Learning Objectives: By the end of this episode, listeners will be able to: Discuss the clinical relevance of long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis.Identify key safety considerations, including herpes zoster, serious infections, MACE, VTE, and malignancy.Describe how age, comorbidities, dose selection, and baseline patient risk influence treatment decisions with oral JAK inhibitors.Explain the role of shared decision-making and risk-benefit communication when treating adolescents, adults, and older patients with AD.Recognize practical considerations around zoster vaccination and routine immunization when initiating JAK inhibitor therapy. 🎧 Tune in for a practical, nuanced, and slightly puppy-interrupted breakdown of what this data actually means for your clinic. #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #Dermatology #JAKInhibitors #Upadacitinib #Rinvoq #EczemaCare #DermTwitter #MedEd #HCPeducation #DermatologyPodcast #Vodcast #ClinicalPearls #SharedDecisionMaking #SkinScience #ADTreatment REFERENCE: Long-Term 6-Year Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis Across Ages: Results From Three Phase 3 Studies ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON DERMATOLOGIST AND PEDIATRICIAN Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program. Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto. Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone. ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON DERMATOLOGIST Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care. Supported by an IME Grant from ABBVIE.. 📻www.skinandjoints.ca✉️info@skinandjoints.ca Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
adbl_web_anon_alc_button_suppression_c
No reviews yet